Navigation Links
Bioenergy Life Science Retains Xsto Solutions to Market D-Ribose
Date:12/11/2008

MINNEAPOLIS, Dec. 11 /PRNewswire/ -- Bioenergy Life Science -- The Ribose Company -- has announced that it has retained Xsto Solutions, LLC, to market Bioenergy D-Ribose(TM) in the Eastern U.S. D-Ribose is a naturally-occurring monosaccharide the body uses to stimulate the synthesis of adenosine triphosphate (ATP) -- an essential energy compound.

"Collaborating with Xsto Solutions will enhance our efforts toward expanding D-Ribose into the marketplace," said Kathy Lund, vice president marketing and sales of Bioenergy Life Science, Ribose Ingredient Division. "D-Ribose is already included in over 100 functional foods and beverages. Aligning ourselves with Xsto Solutions means that more companies will incorporate this natural energy booster."

"Bioenergy D-Ribose is perhaps the most important nutritional discovery of the decade," says Dan Murray, Xsto Solutions vice president of business development. "We're very excited about aggressively expanding the exposure of D-Ribose within the supplement, functional foods and sports nutrition industries."

Although ribose is produced by the body naturally to regulate the synthesis of ATP, it cannot be replenished fast enough during certain forms of demanding exercise. When added to foods and dietary supplements, ribose enhances the body's natural process of energy synthesis. It helps reduce the loss of energy during stress and accelerates energy and tissue recovery.

Bioenergy, which recently achieved GRAS (generally recognized as safe) status for D-Ribose from the U.S. Food and Drug Administration, has amassed a large body of scientific literature regarding uses of ribose for people across all age and health categories. The company has more than 40,000 customers for its proprietary Corvalen(R) products alone, and millions worldwide use Bioenergy D-Ribose in other functional foods like energy bars (Detour, FastFuel, Marathon) and beverages (SoBe Adrenaline Rush, Vitamin Water, Snapple Antioxidant Water).

Bioenergy, Inc. (http://www.bioenergy.com) is a privately held, Minneapolis-based life sciences company whose core technology lies in the development and commercialization of products based on the physiological benefits of D-Ribose for health and wellness. In addition to a pharmaceutical subsidiary, Bioenergy has two other companies. Bioenergy Life Science, Inc. manufactures and sells D-Ribose as an ingredient to nutraceutical firms for beverages and foods; as a medical food through doctors and clinics; and as a dietary supplement for energy recovery (reduces fatigue, muscle pain, soreness and stiffness following exercise). Viacell, LLC is developing technology related to the enhancement of blood components.

Xsto Solutions, LLC (http://www.xstosolutions.com), was established in 2004 and is headquartered in Morristown, New Jersey. Xsto's core focus is bringing a small number of new science-supported nutritional ingredients to the dietary supplement and functional food market. Xsto personnel have successfully and profitably launched new products, driving sales by acting as US-based sales and marketing partners. Xsto has also partnered with small-to medium-sized dietary supplement manufacturers to increase sales and marketing focus.


'/>"/>
SOURCE Bioenergy Life Science
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
2. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
3. Edwards Lifesciences to Present at the Bear Stearns 20th Annual Healthcare Conference
4. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
5. HealthFitness CEO Supports Move Toward Cultural Shift, and Science-Based Health Management Programming
6. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
7. John B. Buse, MD, PhD of Chapel Hill, NC, Elected American Diabetes Association President, Medicine & Science
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. SAMHSA Announces First Science and Service Award Winners
10. Novavax CEO to Present at the 2007 UBS Global Life Sciences Conference
11. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... February 13, 2016 , ... Good news ... first in the area to offer AngioPlex™ Optical Coherence Tomography (OCT) Angiography, imaging ... as macular degeneration, diabetic retinopathy, and other vascular conditions. , In just a ...
(Date:2/13/2016)... ... 2016 , ... Many individuals looking to lead a healthy lifestyle have decreased ... IsoPasta by Isolator Fitness has delved into this niche allowing those giving up their ... IsoPasta has 30 grams of protein and only 7 grams of carbohydrates per ...
(Date:2/13/2016)... , ... February 13, 2016 , ... ... of Nursing with an in-kind gift of a VeinViewer® Vision vein finder ... they learn how to start an IV and draw blood, combining technology with ...
(Date:2/12/2016)... ... ... According to an article published February 4th on mySA, robotically ... hernia repairs throughout the United States. Commenting on this article, Beverly Hills hernia repair ... has not only been expected, but it seems to be a natural result of ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on Monday, February 8, ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... PUNE , Maharashtra, February 12, 2016 /PRNewswire/ ... Market research report titled Chronic Inflammation Global ... and a snapshot of the global clinical trials ... the clinical trials by Region, Country (G7 & ... End point status and reviews top companies involved ...
(Date:2/11/2016)... LONDON , Feb. 11, 2016 The ... current and future adoption patterns on the usage of ... include the following: - Timeframe of liquid ... types—CTCs, ctDNA, cfDNA and Evs—by organization type - Sample ... sample types: blood, saliva, stool, serum, and so on. ...
(Date:2/11/2016)... Feb. 11, 2016 PRO-DEX, INC. (NasdaqCM: PDEX) today ... December 31, 2015. The Company also filed its Quarterly Report ... 2016 with the Securities and Exchange Commission today. ... 2015 --> --> Net ... $2.6 million, or 95%, to $5.4 million from $2.8 million ...
Breaking Medicine Technology: